Treatment News : FDA Updates Atripla Label

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 22, 2013

FDA Updates Atripla Label

The U.S. Food and Drug Administration (FDA) has made changes to the label for the single-pill HIV antiretroviral combination therapy Atripla (efavirenz/emtricitabine/tenofovir). Among those changes and additions are:

  • An advisory against taking Atripla with Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir).
  • Information on drug interaction for raltegravir, boceprevir and telaprevir.
  • Additional information about a rash warning, advising those with a life-threatening reaction such as Stevens-Johnson syndrome to consider alternative HIV therapy.
  • A statement that the appropriate dosing for a combination of efavirenz and boosted Invirase (saquinavir/ritonavir) has not been established.
  • Information about dosing with boosted Kaletra (lopinavir/ritonavir), with an advisory that those taking the pair in combination with Atripla should be monitored for adverse reactions.
  • In an addition to the advisory that HIV-positive mothers should not breast-feed their infants because of the risk of transmitting the virus, the FDA states that studies in rats have shown that efavirenz is secreted in milk and that human studies have shown that both tenofovir and emtricitabine are excreted in breast milk. Because the risks of infant exposure to these agents are unknown, mothers should not breast-feed while taking Atripla.
To read the FDA release, click here.

Search: U.S. Food and Drug Administration, FDA, HIV, Atripla, efavirenz, emtricitabine, tenofovir, Stribild, elvitegravir, cobicistat, raltegravir, boceprevir, telaprevir, Stevens-Johnson syndrome, Invirase, saquinavir, ritonavir, Kaletra, lopinavir, breast-feeding.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.